<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A study has been in progress since June 1985 to evaluate the use of myeloablative therapy (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> [60 mg/kg x 2] and total body irradiation [200 cGy x 6]) followed by reinfusion of autologous bone marrow in patients in second or subsequent remission of B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The marrow mononuclear cell fraction is being treated in vitro with three cycles of the monoclonal antibody anti-CD20 (anti-B1, Coulter Immunology) and baby rabbit complement (Pel-Freez) </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-eight patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (age range 29-61 years, median 43) have been treated to date </plain></SENT>
<SENT sid="3" pm="."><plain>At the time of treatment, 28 patients were in second remission, 7 were in third, and 3 were in more than third remission </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty-three patients were in complete remission, 15 had <z:e sem="disease" ids="C0543478" disease_type="Neoplastic Process" abbrv="">residual disease</z:e> (7 had lymph nodes less than 2 cm diameter, 4 had less than 10% bone marrow infiltration, 1 had involvement of lymph nodes and bone marrow, and 3 had involvement at other sites) </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 38 study patients, 32 are alive; 6 have died, 4 in remission </plain></SENT>
<SENT sid="6" pm="."><plain>Two of the <z:hpo ids='HP_0011420'>deaths</z:hpo> were treatment related: 1 resulted from cerebral haemorrhage at 29 days; 1 resulted from <z:e sem="disease" ids="C0553576" disease_type="Disease or Syndrome" abbrv="">systemic fungal infection</z:e> at three months) </plain></SENT>
<SENT sid="7" pm="."><plain>One patient died from secondary <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous <z:mpath ids='MPATH_336'>leukaemia</z:mpath> at four years, and another from an unrelated cause </plain></SENT>
<SENT sid="8" pm="."><plain>Two patients died following relapse </plain></SENT>
<SENT sid="9" pm="."><plain>The median time to engraftment was 28 days (range 15-45 days) for neutrophils greater than 0.5 x 10(9)/L and 28 days (range 15-46 days) for platelets greater than 20 x 10(9)/L.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>